Exhibitor Listing


Rare Bone Disease Zone             

1, 2 & 3        Ultragenyx Pharmaceutical   


Ultragenyx is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Ultragenyx formed a collaboration with Kyowa Hakko Kirin Co., Ltd. (KHK) to jointly develop and commercialize KRN23 for the treatment of XLH. KRN23 is a fully human monoclonal antibody administered via subcutaneous injection that is designed to bind and thereby reduce the excessive biological activity of FGF23.


Multiple clinical studies of KRN23 in adult patients with XLH have been completed and Ultragenyx and Kyowa Hakko Kirin intend to continue development of KRN23 in adults with XLH. In addition, a Phase 2 study in pediatric patients with XLH is ongoing.

Kyowa Hakko Kirin is a leading biopharmaceutical company in Japan focusing on its core business area of oncology, nephrology, and immunology/allergy. Kyowa Hakko Kirin leverages antibody-related leading-edge technologies to discover and develop innovative new drugs aiming to become a global specialty pharmaceutical company which contributes to the health and well-being of people around the world. 

For more information, please visit www.ultragenyx.com orwww.kyowa-kirin.com.


4, 5 & 6  Alexion    


Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare disorders. Alexion developed and commercializes Soliris® (eculizumab), the first and only approved complement inhibitor to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two life-threatening ultra-rare disorders. As the global leader in complement inhibition, Alexion is strengthening and broadening its portfolio of complement inhibitors, including evaluating potential indications for eculizumab in additional severe and ultra-rare disorders. Alexion’s metabolic franchise includes two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare disorders, Strensiq® (asfotase alfa) to treat patients with hypophosphatasia (HPP) and Kanuma™ (sebelipase alfa) to treat patients with lysosomal acid lipase deficiency (LAL-D). In addition, Alexion is advancing the most robust rare disease pipeline in the biotech industry, with highly innovative product candidates in multiple therapeutic areas.



Imaging & Diagnostics Zone 

7                Faxitron


As the world’s only fully vertically integrated and dedicated cabinet X-ray company, Faxitron is the industry standard. Faxitron systems
offer compact, fully-shielded digital imaging and pre-clinical DEXA systems with the highest resolution (up to 100 lp/mm) and the largest
field of view in the market.

Ultra-high resolution X-ray imaging is an important tool in investigating a variety of disease states. From metastatic cancer to
arthritis and osteoporosis, small animal models are commonly used. Both in vivo and ex vivo planar imaging is used to screen, track, and evaluate structural changes in these studies. Cabinet X-ray systems allow researchers to take images directly in the vivarium to protect the integrity of the colony. These planar imaging systems are less expensive, subject animals to lower doses, and provide faster results than microCT systems.

Faxitron cabinets can be placed directly on the bench top in the lab, or wherever easy access to imaging is needed, no additional
shielding is required. Multiple cabinet and detector sizes with microfocus sources, up to 100kV, make our systems ideal for the full range
of small animal in vivo and ex vivo imaging. As the pioneer in cabinet X-ray, Faxitron has defined the market by developing X-ray sensor
technology and innovative systems to meet the evolving needs of our customers.



10             SCANCO Medical AG


Industry-Leading Provider of microCT (micro-computed tomography) Systems and Solutions.

SCANCO Medical has been a pioneer in the field of high-resolution computed tomography for more than two decades. Starting with the first installation in Switzerland in 1988 we now have systems for medical and industrial applications operating on six continents.

We offer a wide range of microCT scanners for specimen and preclinical as well as clinical use. These systems are supplied with high-end computing equipment and sophisticated analysis and visualization software to provide the most comprehensive and industry-leading imaging solutions.

SCANCO Medical also offers scanning, analysis and consulting services for a wide range of applications.


12              Bruker Micro CT


Bruker microCT develops and manufactures micro and nano-CT scanners both in vivo and ex vivo with high resolution and imaging performance. We also provide a comprehensive software suite for 3D analysis and visualization. Our company was founded in 1996 as “SkyScan” and joined the Bruker family of leading imaging and analytical equipment suppliers in 2012.

Bruker microCT is a trusted solution provider in bone research, attested by hundreds of publications in fields such as osteoporosis, arthritis, orthopedics and dental specialties. More widely we equip researchers throughout life science fields with 3D imaging solutions for both calcified and non-calcified tissues, including multi-modality solutions merging microCT with bioluminescence, fluorescence, PET and SPECT. Our broad product line is founded on three decades at the leading edge of micro-tomography research. Scanners are supplied with comprehensive advanced 3D analysis software featuring high speed GPU reconstruction, versatile volume of interest selection and segmentation tools, measurement of a long list of 3d and 2d parameters and customizable batch operations. In-depth bone research and morphometric support is provided. Bruker-MicroCT customers are closely supported by the global distributors; please visit www.bruker-microct.com for more information.

Other Zone

13    OSTAK Osteologie conference      

Vitamin D  Zone

14 & 15 ECTS   

The ECTS is the major organisation in Europe for researchers and clinicians working in the field of calcified tissues and related fields. For over 50 years the Society has acted as a forum to promote the highest levels of knowledge, research and education through its annual meetings, training courses and grants and awards. Membership of the ECTS is open to anyone working in the field at whatever stage in their career.Come and meet us in Rome at Stand number 14/15. www.ectsoc.org





19              Bruno



Bruno Farmaceutici SpA is a fast-growing Italian pharmaceutical company focused on researching, developing and offering the market advanced therapeutic solutions and improved formulations.Since a long time Bruno is the Italian market leader in the solid oral corticosteroid segment and in the Metformin market for Type-2 diabetes.

In the recent years Bruno has evolved into a more complete and mature company, developing advanced and improved formulations of Alendronate, Flecainide and Ciprofloxacin for otologic use.

Also a new breakthrough technology in the Ophtalmic market for the dry-eye syndrome has been developed and launched internationally in the last two years.

Still based in Italy with a strong focus on the internal market, Bruno ha salso started expanding abroad with the final purpose of making available its products in several markets throughout Europe.


Other Zone                                 

20              AgNovos Healthcare


AgNovos Healthcare is a privately-funded medical device company dedicated to developing innovative treatments for bone health diseases and other therapeutic categories. AgNovos’ global headquarters is in the United States near Washington, D.C. Its European headquarters is in Zurich, Switzerland.  The Company was founded in 2012 by renowned orthopedic surgeon Dr. James Howe.  Through scientific rigor and the compassion born of Dr. Howe’s decades of working with patients, AgNovos aims to reduce the devastating personal and societal costs of diseases like osteoporosis. The company is developing innovative treatments that have the potential to alter the landscape of bone health. By bringing new technology to market, the company strives to help patients maintain their mobility and independence.

21              CeGaT


As a human genetic diagnostics provider we offer the decoding of genetic information and its medical interpretation. In 2010 we became the first company to establish high-throughput sequencing in human genetic diagnostics. Using this technology it is possible to analyze many regions of the genome simultaneously.

For our Diagnostic Panels we use state of the art next-generation sequencing (NGS) technology to simultaneously analyze all known genes associated with a certain disease. This approach is much faster and cheaper than conventional methods.

In addition to Diagnostic Panels we also offer Tumor Diagnostics, Exome Diagnostics and Single Gene Testing.


23              Stratec Medizintechnik GmbH (TBC)   


Stratec Medizintechnik is the world´s most successful producer of pQCT-based
bone densitometry scanners for clinical and preclinical applications. These systems
offer more than convent ional 2-dimensional bone densitometry. Results are
presented in real density units (g/cm³) . Unlike in 2-dimensional absorptiometric
machines pQCT derived density measures are independent of bone size. Therefore
pQCT can be applied to al l age groups and body sizes. Additionally geometical
properties of bone can be analysed which enables the user to estimate noninvasively bone´s mechanical proper ties. The combined analysis of muscle and
bone parameters al lows a detailed diagnosis and the differentiation of disuse
osteopenia from true osteoporosis.

The sister company Novotec Medical is manufacturer of Galileo vibration training
devices for muscle stimulation and of Leonardo mot ion analysis systems
(mechanography) . Due to the side alternating technology a natural movement
similar to human gait is employed. Improvement of muscle force and power ,
treatment of back pain and abatement of immobility are typical fields of application.
Short training times and fast success make it an ideal tool for corporate health

For more than 25 years the consolidated companies collaborate closely with
international research facilities. The realised results are continuously incorporated
in our products.

pQCT bone density and geometry, Leonardo mechanography and Galileo training
are building blocks of a holistic concept for diagnosis and therapy of
musculoskeletal disorders.

The portfol io of imaging, mot ion analysis and Galileo t raining adds up to a holistic
concept around the issue of muscle and bone, ranging from diagnosis to treatment .
Novotec Medical is project partner of ESA ( European Space Agency) in several
projects e.g. for the evaluation of efficient t raining measures to avoid muscle and
bone loss during space missions and collaborates worldwide with other renowned
research facilities like Charite´ Berlin, university clinic Cologne and ETH Zuerich.


24                 Mindway CT

MindwaysCT is an industry leader and technology innovator, providing physicians with systems that enable the fully quantitative assessment of CT images. Mindways continues research and development efforts to advance quantitative CT (QCT) technologies for new and innovative applications.


MindwaysCT premier product, QCT Pro™ is the market leader in quantitative CT bone mineral density analysis. QCT Pro™ is uniquely designed to guide the user through an intuitive workflow to quickly and efficiently produce BMD patient reports. QCT Pro™ hip BMD measurements are interpreted in the same manner as DXA measurements, while volumetric spine measurements provide exceptional sensitivity to short-term bone density change.

MindwaysCT Asynchronous QCT Pro is the next generation of QCT: a patient phantom is not required during the scan. Monthly phantom scans are used to calibrate patient scans independently of the patient. Asynchronous QCT further simplifies workflow, and it facilitates opportunistic, dual-use and retrospective BMD measurement from CT scans. Asynchronous QCT allows a spine and/or hip BMD measurement to be extracted from non-IV contrast CT scans done for other indications, including abdomen/pelvis/spine CT, CT colonography, CT urography, LDCT, cancer related PET CT, among others. More than 24 million such CT scans are done annually in the U.S. and most of these are in an at-risk patient population.

This presents an opportunity to greatly increase osteoporosis screening with no additional radiation dose to the patient. PACS archives can be used to obtain BMD estimates on CT scans done days, weeks or years ago. Associations between BMD and clinical outcomes can be obtained. Patients with previously unappreciated low bone mass that might benefit from a follow-up BMD study are identified. Asynchronous QCT is a cost-effective bone-health program whether it is used as a standalone screening program or as a tool for identifying patients, that might benefit from specialty bone-health services.


25 & 26             MSD


Today's Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit www.merck.com and connect with us on Twitter, Facebook and YouTube.

MSD, Kenilworth, NJ 07033. USA   www.merck.com